Reviva Pharmaceuticals -CW23RVPHWPreferred / convertible
13F holders, Q3 2024 (September 30)3holders −1
0new positions
0sold out
$0.14avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Reviva Pharmaceuticals -CW23 (RVPHW) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 0 sold out. The largest holders were Walleye Capital LLC ($5K), Walleye Trading LLC ($3K) and UBS Group AG ($90).
- Company
- Reviva Pharmaceuticals -CW23
- CUSIP
- 76152G118
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 3,995 shares sold, net −3,995 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Walleye Capital LLC | — | No change | 33,718 | $5K |
| Walleye Trading LLC | — | No change | 25,727 | $3K |
| UBS Group AG | — | Reduce -85.7% | 666 | $90 |
"% of holder's portfolio" is RVPHW's weight in each manager's 13F, not the share of Reviva Pharmaceuticals -CW23 the manager owns.